Navigation Links
OncoSec Medical Appoints Engineering Leader
Date:7/5/2011

SAN DIEGO, July 5, 2011 /PRNewswire/ -- OncoSec Medical Inc. (OTCBB: ONCS), which is developing its advanced-stage ElectroOncology therapies to treat solid tumor cancers, announced today the appointment of Brian McCluskey as Executive Director, Engineering, who will lead the development of the company's proprietary electroporation delivery technology, the OncoSec Medical System (OMS).

(Logo: http://photos.prnewswire.com/prnh/20110314/MM64943LOGO)

Punit Dhillon, OncoSec's President and CEO, said, "We are pleased that Brian will join  our management team. He brings a proven track record of medical device design and technical leadership experience, with the ability to design, manage and coordinate the development of medical devices from concept to production. Brian will be instrumental in developing OncoSec's next generation OMS products."

OncoSec's minimally invasive ElectroOncology therapies utilize its proprietary electroporation delivery system, called the OncoSec Medical System (OMS), which applies short electrical impulses to selectively targeted tumors and tissue in order to significantly increase the ability of anti-cancer chemotherapeutic or biologic agents to enter into cells. These treatments selectively destroy cancer cells while preserving healthy tissue. They optimize required dosage and potentially reduce treatment and post-treatment costs.

Brian McCluskey, Executive Director, Engineering

Mr. McCluskey has more than 30 years of electrical engineering experience, in which he has spent the last 20 years developing software and hardware for devices used for medical and research purposes. Through this, he has managed successful submissions for FDA 510(k) approvals, as well as, CE marks for marketing in Europe. Mr. McCluskey was recently with Teledyne RD Instruments (TRDI), a leader in the design and manufacture of Doppler instrumentation, for which he managed custom production for TRDI clients. He was also engineering manager for Digirad Corporation, a leading manufacturer of solid-state gamma cameras and cardiology imaging software, for which he managed product development from early conception to product release leading to multi-million dollar revenue in his first year.

Mr. McCluskey will lead OncoSec's team of engineers and manufacturing operations as well as work closely with the company's Quality Assurance department.

About OncoSec Medical Inc.

OncoSec Medical (OTCBB: ONCS) develops novel ElectroOncology therapies that combine its proprietary electroporation delivery technology with a chemotherapeutic or novel DNA-based immunotherapeutics. Targeted local delivery of these agents is designed to achieve selective destruction of cancerous tumors while sparing healthy normal tissue, resulting in improved functional, cosmetic and quality of life outcomes. These therapies have achieved validating safety and efficacy data in early and late stage clinical studies of over 400 cancer patients. OncoSec's clinical programs include three Phase II clinical trials. More information is available at www.oncosec.com.

This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition and market conditions. These and additional risks and uncertainties are more fully described in OncoSec's filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward looking statements which speak only as of the date they are made. OncoSec disclaims any obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE OncoSec Medical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. OncoSec Medical Announces the Appointment of Dr. Anthony E. Maida, III, to Its Board of Directors
2. OncoSec Medical Closes Purchase and License Agreement for Tumor Therapy Technology with Inovio Pharmaceuticals
3. OncoSec Medical Closes $1.1M Financing
4. OncoSec Medical to Present at ROTH 23rd Annual Growth Stock Conference
5. Inovio Pharmaceuticals Licenses Non-DNA Vaccine Tumor Therapy Technology to OncoSec Medical
6. OncoSec Medical Licenses Non-DNA Vaccine Tumor Therapy Technology from Inovio Pharmaceuticals
7. Ansell Limited Acquires Sandel Medical Industries LLC, an Innovator in Surgical Safety Solutions
8. Sonitus Medical Receives Second FDA Clearance for SoundBite™ Hearing System
9. Qmed Profiles Searchable Across All Medical Device Websites
10. MarketsandMarkets: Global Top 10 Medical Devices Market (2010 - 2015)
11. Global Medical Imaging Launches Worlds First Ultrasound Maintenance App
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2017)... 2017 It should come as no surprise to ... in the midst of a crippling opioid epidemic. According to ... number of overdose deaths from opiate-based medications has quadrupled, Says, ... million dead from 2001 to 2015". During this time, the ... similarly quadrupled, drawing a compelling link between prescription and eventual ...
(Date:7/12/2017)... is a revolutionary new product that relieves painful carpal tunnel syndrome ... affects more than 8 million people a year. Women suffer from ... methods of treating CTS are painful surgery, the use of NSAIDs ... ... a clear patch worn on the palm of the hand. It ...
(Date:7/11/2017)... Md. , July 11, 2017  The global ... estimated revenues of approximately $394.1 million in 2016.  Although ... trend of solid growth, in particular as a result ... clinical practice, and the recent introduction of a significant ... need for less-invasive testing of tumor biomarkers to guide ...
Breaking Medicine Technology:
(Date:7/24/2017)... ... 24, 2017 , ... Anyone who uses scales know they have limits; a ... using that same scale to dispense medication. The first example is an issue of ... why it is important to have the right balance for the process. METTLER TOLEDO’s ...
(Date:7/24/2017)... Calif. (PRWEB) , ... July 24, 2017 , ... A ... from food addiction to sexual abuse, and how she has overcome them. “Forbidden Memories: ... instances in her life and how she has risen above. , In “Memories,” readers ...
(Date:7/24/2017)... ... July 24, 2017 , ... Right now, behind ... The agency is hammering out a game plan to implement changes and compromises ... to affect FDA-regulated firms. The new law:, ,     Seeks ways ...
(Date:7/24/2017)... ... , ... “A Short Walk to the Mailbox”: a remarkable memoir of an ... author, Ed Clark. Ed Clark is a church music director and choral conductor. ... of music and worship leader for over fifty years. He has a master’s ...
(Date:7/23/2017)... (PRWEB) , ... July 23, 2017 , ... A ... in St. Louis, and led by the Minneapolis Veterans Administration Health Care System overwhelmingly ... of the disease offers very few benefits. , In the cases involved with ...
Breaking Medicine News(10 mins):